Patients who are examined in the neurological sleep laboratory due to a sleep disorder. G47.0 G47.2 G47.3 G47.8 F51.0 F51.2 F51.3 F51.8
Conditions
Interventions
Group 1: Age group 20 - 39 years
MR-S (magnetic resonance spectroscopy) using MRI (evening and morning)
Symbol Digit Modalities Test - SDMT (evening and morning)
Trail Making Test - TMT (evening and m
Sponsors
Universitätsklinikum Carl Gustav Carus Dresden
Eligibility
Sex/Gender
All
Age
20 Years to 79 Years
Inclusion criteria
Inclusion criteria: Existence of a written declaration of informed consent after the information has been provided Sufficient knowledge of German (neuropsychological testing takes place in German)
Exclusion criteria
Exclusion criteria: Relevant neurological diseases of the central nervous system in the past (e.g. stroke, epilepsy, manifest neurodegenerative disease, narcolepsy) Taking centrally active medication that has an influence on the sleep EEG or transmitter expression (e.g. sedatives, anticonvulsants, antidepressants, neuroleptics) (Untreated) severe sleep-related breathing disorders (AHI > 30/h) Unfeasibility of the MRI examination (e.g. claustrophobia or pacemaker)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative reduction of the slow-wave activity (SWA) determined in the sleep EEG during the night. Circadian change (evening vs. morning) in the glutamate concentration determined by MR-S in two cortex regions (frontal left, parietal right). | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between cognitive performance (SDMT and TMT) or cognitive reserve (CRIq) and the parameters of synaptic homeostasis (SWA reduction, Glu decrease). | — |
Countries
Germany
Contacts
Public ContactMoritz Brandt
Universitätsklinikum Carl Gustav Carus Dresden
Outcome results
None listed